Buckingham Research upgrades Omnicare (NYSE: OCR) from Neutral to Accumulate. Price target $25.

Buckingham analyst, Claire Mencke, says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE